Everest Re Group, Ltd. (RE)
(Delayed Data from NYSE)
$238.66 USD
+1.87 (0.79%)
Updated May 3, 2019 04:02 PM ET
After-Market: $238.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$238.66 USD
+1.87 (0.79%)
Updated May 3, 2019 04:02 PM ET
After-Market: $238.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Is Everest Re Group (RE) Down 5.8% Since Its Last Earnings Report?
by Zacks Equity Research
Everest Re Group (RE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Everest Re (RE) Issues Catastrophe Loss Estimates for Q1
by Zacks Equity Research
Everest Re's (RE) projected catastrophe loss for the first quarter of 2018 might mar the prospects of the company's impending results.
Here's Why Radian Group (RDN) is a Lucrative Investment Pick
by Zacks Equity Research
Radian Group (RDN) has potential to thrive on better insurance in force, declining claim payments as well as a sturdy capital position. This in turn raises optimism among investors on the stock.
Lap Up These 4 Lucrative Insurance Gems Ahead of Q1 Earnings
by Tanuka De
We zoom in on four insurance stocks to enhance your portfolio ahead of Q1 reporting cycle.
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
by Zacks Equity Research
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
Boost Immunity to Market Volatility With 5 Low-Beta Stocks
by Zacks Equity Research
We have developed a strategy which clearly shows that stocks with low risk could also reward investors with handsome returns.
Everest Re Group (RE): Moving Average Crossover Alert
by Zacks Equity Research
Everest Re Group, Ltd. (RE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
5 Reasons Why Travelers Stock Fits Your Portfolio to the Tee
by Zacks Equity Research
Travelers Companies (TRV) looks promising as a better-yielding stock owing to five solid factors.
W. R. Berkley Corp. vs. Alleghany: Which Is a Better Insurer?
by Zacks Equity Research
On comparative assessment, we try and find out which stock W. R. Berkley Corporation (WRB) or Alleghany Corporation (Y) - is better positioned in terms of fundamentals.
6 Reasons Why You Should Retain Chubb (CB) in Your Portfolio
by Zacks Equity Research
Chubb Limited (CB) promises to offer solid yields on the back of six factors.
6 Reasons Why You Should Hold AXIS Capital in Your Portfolio
by Zacks Equity Research
Riding high on six factors, AXIS Capital (AXS) holds potential to generate better returns to investors.
First American (FAF) Stock Surges 62% in a Year: Here's Why
by Zacks Equity Research
First American Financial's (FAF) shares rise more than 62% in a year, driven by solid fundamentals and favorable industry trends.
Should You Get Rid of Atlas Financial Holdings (AFH) Now?
by Zacks Equity Research
Atlas Financial (AFH) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Here's Why Everest Re is an Attractive Investment Option
by Zacks Equity Research
Compelling fundamentals and undervaluation of shares make Everest Re (RE) an attractive investment bet.
Everest Re Group (RE) Up 5.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Everest Re Group (RE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Everest Re vs. XL Group: Which Stock Is the Stronger Bet?
by Zacks Equity Research
On a comparative analysis, we try and find out which stock -- Everest Re (RE) or XL Group (XL) -- is better positioned in terms of fundamentals.
Here's Why You Should Hold on to Everest Re (RE) Stock Now
by Zacks Equity Research
Everest Re (RE) remains well-poised for growth riding high on solid segmental performances.
Why Is Everest Re (RE) Down 2.5% Since the Last Earnings Report?
by Zacks Equity Research
Everest Re (RE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Should You Hold Everest Re (RE) Stock Right Now?
by Zacks Equity Research
Everest Re's (RE) solid premium growth, improving AUM and robust capital management continue to impress. However, exposure to cat losses remains a concern.
Everest Re (RE) Q2 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Increase in premiums, double-digit return on equity, and improvement in combined ratio and book value are reflected in the second-quarter results of Everest RE Group Ltd (RE).
Why Earnings Season Could Be Great for Everest Re Group, Ltd. (RE)
by Zacks Equity Research
Recent earnings estimate revisions suggest that good things are ahead for Everest Re, and that a beat might be in the cards for the upcoming report.
Is Everest Re Group, Ltd. (RE) a Suitable Value Stock Now?
by Zacks Equity Research
Let's put Everest Re Group, Ltd. (RE) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Why is Hold Strategy Apt for Everest Re (RE) Stock Now?
by Zacks Equity Research
Shares of Everest Re Group, Ltd. (RE) rallied 17.10% year to date, significantly outperforming the Zacks categorized Property and Casualty Insurance industry's increase of 3.89%.
Everest Re Group (RE) to Join the S&P 500, Stock Gains
by Zacks Equity Research
Everest Re Group Ltd. (RE) is set to join S&P 500, replacing Mead Johnson Nutrition Co. (MJN) after the trading closes on Friday, Jun 16.
Everest Re's (RE) Prospects Look Bright: Should You Hold?
by Zacks Equity Research
Shares of Everest Re Group, Ltd. (RE) gained 3.43% since the release of first-quarter 2017 results, outperforming the Zacks categorized Property and Casualty Insurance industry's increase of 0.01%.